Effective antitumor immunity is recognized to require the existence and activation of a variety of immune cells, including B cells, CD8+ T cells, and CD4+ T cells, etc. This concept is confirmed by the presence of intratumoral tertiary lymphoid structures (TLSs), which are well-organized tumor-infiltrating lymphocyte (TIL) clusters and may generate an advanced immune response (3). The gene discussed is CD8A; the disease is neoplasm.